Helixate

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2018
01219982018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Essentials Factor VIII inhibitors are the most serious complication in patients with hemophilia A. Aggregates in… (More)
Is this relevant?
2015
2015
Although it has been suggested that switching of factor VIII (FVIII) products may increase inhibitor formation this is disputed… (More)
Is this relevant?
2014
2014
The administration of therapeutic factor VIII (FVIII) to treat or prevent haemorrhages in haemophilia A patients results, in up… (More)
Is this relevant?
2014
2014
patient decide. Inhibitor formation is a multicausal process and FVIII exposure is undeniably a necessary cause of inhibitors… (More)
Is this relevant?
Review
2008
Review
2008
Sucrose-formulated octocog alfa (Kogenate Bayer, Kogenate FS, Helixate FS, Helixate nexgen) is a full-length recombinant human… (More)
Is this relevant?
Review
2001
Review
2001
The state-of-the-art treatment for hemophilia A is replacement therapy with recombinant factor VIII (rFVIII) made possible by… (More)
Is this relevant?
1998
1998
Recombinant hirudin (rH) is a highly specific thrombin inhibitor which is under clinical investigation for various thrombotic… (More)
Is this relevant?